[go: up one dir, main page]

PE20081382A1 - ANGIOTENSIN II RECEPTOR ANTAGONISTS - Google Patents

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Info

Publication number
PE20081382A1
PE20081382A1 PE2007001778A PE2007001778A PE20081382A1 PE 20081382 A1 PE20081382 A1 PE 20081382A1 PE 2007001778 A PE2007001778 A PE 2007001778A PE 2007001778 A PE2007001778 A PE 2007001778A PE 20081382 A1 PE20081382 A1 PE 20081382A1
Authority
PE
Peru
Prior art keywords
bis
alkyl
nitrooxy
imidazol
biphenyl
Prior art date
Application number
PE2007001778A
Other languages
Spanish (es)
Inventor
Iyassu K Sebhat
Ravi P Nargund
Amjad Ali
Chris Franklin
Nicoletta Almirante
Laura Storoni
Silvia Stefanini
Lo Michael Man-Chu
Original Assignee
Merck & Co Inc
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Nicox Sa filed Critical Merck & Co Inc
Publication of PE20081382A1 publication Critical patent/PE20081382A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BIS(NITROOXI) DE FORMULA (I) DONDE R ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS; Y ES -Y1-Y2-Y3-Y4-Y5-, DONDE Y1 ES C(R1R2); R1 ES H O ALQUILO(C1-C4); R2 ES H, ALQUILO(C1-C4) O -OC(O)ALQUILO(C1-C4); Y2 ES O, C(O), P(O)(OH) O CH2; Y3 ES O, C(O) O CH2; Y4 ESTA AUSENTE O ES O, CH2; Y5 ESTA AUSENTE O ES -(CH2)1-2-(X)0-1-(CH2)0-1, DONDE X ES -O- O -CR3R4-; R3 Y R4 SON CADA UNO H O ALQUILO(C1-C4). SON COMPUESTOS PREFERIDOS: 1-[({[(5S)-5,6-BIS(NITROOXI)HEXIL]OXI}CARBONIL)OXI]ETIL 2-BUTIL-4-CLORO-1-{[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL}-1H-IMIDAZOL-5-CARBOXILATO, 1-[({2-[2,3-BIS(NITROOXI)PROPOXI]ETOXI}CARBONIL)OXI]ETIL 2-BUTIL-4-CLORO-1-{[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL}-1H-IMIDAZOL-5-CARBOXILATO, 1-[({[3,3-DIMETIL-5,6-BIS(NITROOXI)HEXIL]OXI}CARBONIL)OXI]ETIL 2-BUTIL-4-CLORO-1-{[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL}-1H-IMIDAZOL-5-CARBOXILATO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ANGIOTENSINA II SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, INSUFICIENCIA RENAL, ATEROESCLEROSISREFERS TO COMPOUNDS DERIVED FROM BIS (NITROOXI) OF FORMULA (I) WHERE R IS A COMPOUND OF FORMULA (i), (ii), AMONG OTHERS; Y IS -Y1-Y2-Y3-Y4-Y5-, WHERE Y1 IS C (R1R2); R1 IS HO (C1-C4) ALKYL; R2 IS H, (C1-C4) ALKYL O -OC (O) (C1-C4) ALKYL; Y2 IS O, C (O), P (O) (OH) O CH2; Y3 IS O, C (O) O CH2; Y4 IS ABSENT OR IS O, CH2; Y5 IS ABSENT OR IS - (CH2) 1-2- (X) 0-1- (CH2) 0-1, WHERE X IS -O- OR -CR3R4-; R3 AND R4 ARE EACH H OR ALKYL (C1-C4). PREFERRED COMPOUNDS ARE: 1 - [({[(5S) -5,6-BIS (NITROOXY) HEXYL] OXI} CARBONYL) OXY] ETHYL 2-BUTYL-4-CHLORO-1 - {[2 '- (1H-TETRAZOLE -5-IL) BIPHENYL-4-IL] METHYL} -1H-IMIDAZOL-5-CARBOXYLATE, 1 - [({2- [2,3-BIS (NITROOXY) PROPOXI] ETOXY} CARBONYL) OXY] ETHYL 2-BUTYL -4-CHLORO-1 - {[2 '- (1H-TETRAZOLE-5-IL) BIPHENYL-4-IL] METHYL} -1H-IMIDAZOL-5-CARBOXYLATE, 1 - [({[3,3-DIMETHYL- 5,6-BIS (NITROOXY) HEXYL] OXI} CARBONYL) OXY] ETHYL 2-BUTYL-4-CHLORO-1 - {[2 '- (1H-TETRAZOL-5-IL) BIPHENYL-4-IL] METHYL} - 1H-IMIDAZOL-5-CARBOXYLATE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR, BEING USEFUL IN THE TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, KIDNEY FAILURE, ATHEROSCLEROSIS

PE2007001778A 2006-12-13 2007-12-12 ANGIOTENSIN II RECEPTOR ANTAGONISTS PE20081382A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87463006P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
PE20081382A1 true PE20081382A1 (en) 2008-09-18

Family

ID=39536882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001778A PE20081382A1 (en) 2006-12-13 2007-12-12 ANGIOTENSIN II RECEPTOR ANTAGONISTS

Country Status (18)

Country Link
US (2) US20100152259A1 (en)
EP (1) EP2121665B1 (en)
JP (1) JP2010513274A (en)
KR (1) KR20090103916A (en)
CN (1) CN101547918A (en)
AR (1) AR064306A1 (en)
AU (1) AU2007334522B2 (en)
CA (1) CA2671673A1 (en)
CL (1) CL2007003613A1 (en)
DO (1) DOP2009000139A (en)
EA (1) EA200900808A1 (en)
MX (1) MX2009006210A (en)
NO (1) NO20092638L (en)
PE (1) PE20081382A1 (en)
TN (1) TN2009000236A1 (en)
TW (1) TW200831079A (en)
WO (2) WO2008076247A2 (en)
ZA (1) ZA200904479B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
AR069340A1 (en) * 2007-11-26 2010-01-13 Merck & Co Inc ANGIOTENSIN II RECEIVER ANTAGONISTS
US20110077279A1 (en) * 2008-06-09 2011-03-31 Nicoletta Almirante Angiotensin ii receptor antagonists
AR073259A1 (en) * 2008-07-29 2010-10-28 Merck & Co Inc USEFUL FUROSEMIDE DERIVATIVES AS DIURETICS
JP2012511002A (en) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション Nitrooxy derivatives as angiotensin II receptor antagonists
RU2406435C1 (en) * 2009-09-10 2010-12-20 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Pharmacological correction of sympathetic hypertonus associated calcium antagonists prescribed in patients with combined arterial hypertension and bronchial asthma
JO3350B1 (en) 2011-03-07 2019-03-13 Merck Sharp & Dohme Heterocyclic derivatives containing primary amino groups and diazeniumdiolates
CN105218527B (en) * 2015-10-10 2018-04-24 江苏宝众宝达药业有限公司 A kind of preparation method of EXP-3174

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
IT1243367B (en) 1990-07-26 1994-06-10 Italfarmaco Spa BENZOIC ACID DERIVATIVES SUBSTITUTED FOR CARDIOVASCULAR ACTIVITY
IT1295694B1 (en) * 1996-11-14 1999-05-27 Nicox Sa NITROXIS DERIVATIVES FOR THE PREPARATION OF MEDICATIONS WITH ANTI-THROMBINIC ACTIVITY
IT1311924B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311923B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1314184B1 (en) * 1999-08-12 2002-12-06 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS
EP1603933A2 (en) * 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
KR20060056352A (en) 2003-07-31 2006-05-24 니콕스 에스. 에이. Angiotensin II Receptor Blocker Derivatives
EP1668008A4 (en) 2003-08-28 2009-02-25 Nitromed Inc Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
CN1914149A (en) * 2004-01-27 2007-02-14 默克弗罗斯特公司 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
WO2006079610A1 (en) 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
AU2006216665A1 (en) * 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
US20070032533A1 (en) * 2005-08-08 2007-02-08 Nitromed, Inc. Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
EP2121664B1 (en) * 2006-12-13 2013-10-16 Merck Sharp & Dohme Corp. Dinitrate derivatives as angiotensin ii receptor antagonists
AR069340A1 (en) * 2007-11-26 2010-01-13 Merck & Co Inc ANGIOTENSIN II RECEIVER ANTAGONISTS

Also Published As

Publication number Publication date
WO2008076246A3 (en) 2009-01-15
ZA200904479B (en) 2010-09-29
WO2008076247A2 (en) 2008-06-26
CL2007003613A1 (en) 2008-07-11
AU2007334522B2 (en) 2012-03-15
MX2009006210A (en) 2009-07-22
US20080194660A1 (en) 2008-08-14
DOP2009000139A (en) 2009-08-31
KR20090103916A (en) 2009-10-01
AU2007334522A1 (en) 2008-06-26
WO2008076247A3 (en) 2009-01-15
EA200900808A1 (en) 2009-12-30
CA2671673A1 (en) 2008-06-26
EP2121665B1 (en) 2014-01-22
US20100152259A1 (en) 2010-06-17
TN2009000236A1 (en) 2010-10-18
AR064306A1 (en) 2009-03-25
US7880014B2 (en) 2011-02-01
EP2121665A2 (en) 2009-11-25
CN101547918A (en) 2009-09-30
TW200831079A (en) 2008-08-01
NO20092638L (en) 2009-09-11
WO2008076246A2 (en) 2008-06-26
JP2010513274A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
PE20081382A1 (en) ANGIOTENSIN II RECEPTOR ANTAGONISTS
PE20120620A1 (en) DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES
PE20120403A1 (en) ARYL-PYRIDINES AS INHIBITORS OF ALDOSTERONE SYNTHASE
PE20100239A1 (en) BENZOQUINAZOLINE DERIVATIVES AS PROMOTERS OF PARATHYROID HORMONE RELEASE
PE20090042A1 (en) CYCLOPAMINE ANALOGS
WO2008146871A1 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
AR065649A1 (en) HERBICIDLY ACTIVE CYCLE DIONS, OBTAINING PROCESSES AND COMPOSITIONS.
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
ATE554085T1 (en) NEW INHIBITORS OF GLUTAMINYL CYCLASE
ATE429427T1 (en) PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
ATE506354T1 (en) SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS
PE20081227A1 (en) INDAZOLYL SULPHONAMID DERIVATIVES AS MODULATORS OF GLUCOCORTICOIDES
PE20061353A1 (en) SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS
AR066014A1 (en) DIFENIL- DIHIDRO -IMIDAZOPIRIDINONES. PHARMACEUTICAL COMPOSITIONS AND USES.
EA200700047A1 (en) NEW ALKYL DERIVATIVES AS METABOTROPIC GLUTAMAT RECEPTORS
MA34078B1 (en) Areletinyl derivatives
PE20091309A1 (en) CYCLOHEXYL DERIVATIVES AS ACETYL COENZYME CARBOXYLASE INHIBITORS
AR065280A1 (en) ANTIPARASITARY AGENTS
ATE500251T1 (en) BENZIMIDAZOLES AND THEIR USE IN THE TREATMENT OF DIABETES
NO20060195L (en) Quinolylamide derivatives as CCR-5 antagonists
AR060379A1 (en) COMPOUND AND HERBICIDE COMPOSITION
TW200732309A (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
ATE512142T1 (en) PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATIN RECEPTOR ACTIVITY
HRP20080027T3 (en) 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID (4-METHOXY-7-MORPHOLIN-4-IL-BENZOTIAZOL-2-IL) -AMIDE
MX2010012421A (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethyl amino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinam ide as nk1 receptor antagonists.

Legal Events

Date Code Title Description
FC Refusal